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Abstract: A new series of compounds characterized by the presence of a 2-
methoxy/ethoxycarbonyl group, combined with either no substituent or a methoxy group at 
each of the four possible positions of the benzene portion of the 3-(3’,4’,5’-
trimethoxyanilino)benzo[b]furan skeleton, were evaluated for antiproliferative activity against 
cancer cells in culture, and, for selected, highly active compounds, inhibition of tubulin 
polymerization, cell cycle effects and in vivo potency. The greatest antiproliferative activity 
occurred with a methoxy group introduced at the C-6 position, the least with this substituent 
at C-4. Thus far, the most promising compound in this series was 2-methoxycarbonyl-3-
(3’,4’,5’-trimethoxyanilino)-6-methoxybenzo[b]furan (3g), which inhibited cancer cell growth 
at nanomolar concentrations (IC50’s, 0.3-27 nM), bound to the colchicine site of tubulin, 
induced apoptosis and showed, both in vitro and in vivo, potent vascular disrupting properties 
derived from the effect of this compound on vascular endothelial cells. Compound 3g had in 
vivo antitumor activity in a murine model comparable to the activity obtained with 
combretastatin A-4 phosphate.  
 3 
Introduction 
Microtubules, dynamic cellular structures in neoplastic and non-neoplastic cells, are generated 
by the polymerization of ,-tubulin heterodimers.1,2 Besides being critical for cell 
architecture, the microtubule system is essential for cell division, being the major component 
of the mitotic spindle, and for fundamental cellular processes, such as regulation of motility, 
cell signaling, secretion and intracellular transport.
3-5
 A significant number of antimitotic 
agents, many of which are natural products, interact specifically with tubulin and are able to 
affect tubulin polymerization.
6-8
 More recent studies have demonstrated that several small 
molecules able to interfere with the dynamic assembly of tubulin in generating the 
microtubule system are also able to induce extensive morphological changes in the endothelial 
cells of tumor vasculature. Such agents can thus also be classified as vascular disrupting 
agents (VDA).
9-12
 The cis-stilbene natural product combretastatin A-4 (CA-4, 1, Chart 1), 
isolated by Pettit et al. from the bark of the South African bush willow tree Combretum 
caffrum,
13
 strongly inhibits tubulin polymerization through binding to the colchicine site of 
tubulin.
14
 CA-4 shows strong growth inhibition against a variety of cancer cells, including 
multidrug resistant cancer cell lines.
15
 A water-soluble disodium phosphate ester derivative of 
1a (named CA-4P, 1b) has shown promising results in clinical trials.
16
 CA-4P is under 
evaluation in phase III trials for the treatment of anaplastic thyroid cancer and in phase II trials 
for non-small cell lung cancer and platinum-resistant ovarian cancer.
17,18
 
Previous studies have yielded series of chemically diverse small molecules based on the 
benzo[b]furan scaffold, and the most active of these compounds act as antimitotic agents.
19-21
 
The 3-(3’,4’,5’-trimethoxybenzoyl)-6-methoxybenzo[b]furan molecular skeleton was the core 
structure of a series of antitubulin agents with general structure 2 identified by Pinney and co-
workers as potent inhibitors of both tubulin polymerization and cell proliferation of the MCF-
 4 
7 and MDA-MB-231 cancer cell lines.
22-24
 While at the C-2 position there was a wide 
tolerance to structural variation with hydrophobic and hydrophilic substituents, at the C-3 
position the carbon linker with the 3’,4’,5’-trimethoxyphenyl substituent was more effective 
as a carbonyl group than as a carbinol or a simple methylene group.
22
 Previous studies have 
shown that the concomitant presence of a C-6 methoxy substituent significantly contributed to 
maximal activity, presumably as a mimic of the 4-methoxy group in the B-ring of CA-4.
23
 The 
introduction of a hydroxyl at the C-7 position was well tolerated and afforded compounds 
with similar potency for R2=H, while a 10-fold increase in activity was observed for R2=OH. 
Among the synthesized compounds, the C-2 methoxycarbonyl analogue 2a showed potent 
activity in inhibiting the growth of the MDA-MB-231 human breast cancer cell line (IC50: 1-
10 nM). Moreover, 2a had no significant selectivity against activated over quiescent human 
umbilical vein endothelial cells (HUVECs) (IC50: 1-10 nM).
25
 These findings prompted us to 
analyze this class of compounds in more detail. Specifically, we were intrigued by the idea of 
studying the biological effects of replacing the carbonyl group at the C-3 position of 
compound 2a by an anilinic nitrogen (NH) moiety with hydrogen-bond accepting and 
donating capability, to furnish a new series of 2-methoxy/ethoxycarbonyl-3-(3’,4’,5’-
trimethoxyanilino)benzo[b]furan derivatives with general structure 3. By the synthesis of this 
series of compounds, we focused on the effects on antiproliferative activity obtained by the 
insertion of an electron-donating methoxy substituent at the C-4, C-5, C-6 or C-7 positions, 
combined with the methoxy/ethoxycarbonyl substitution at the C-2 position of the 
benzo[b]furan nucleus. In this new class of compounds, the anilinic hydrogen at the C-3 
position was also potentially able to generate an internal hydrogen bond with the sp2-oxygen 
of the alkoxycarbonyl moiety.  
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Chemistry  
Compounds 3a-l were synthesized by a two-step procedure described in Scheme 1. The 
condensation of 2-hydroxy benzonitrile derivatives 4a-f 
21
with methyl or ethylbromoacetate 
and K2CO3 in DMF furnished by a tandem “one-pot” cyclization procedure the 2-
methoxy/ethoxycarbonyl-3-amino benzo[b]furan derivatives 5a-l in good yields. Finally, the 
novel derivatives 3a-l were prepared using the C-N Buchwald-Hartwig palladium catalyzed 
cross-coupling protocol,
 
by reaction of deactivated 3-amino benzo[b]furan analogues 5a-l 
with 1-bromo-3,4,5-trimethoxybenzene, in the presence of Pd(OAc)2, rac-BINAP and Cs2CO3 
(as catalyst, ligand and base, respectively) in toluene at 100 °C.  
Biological Results and Discussion 
In vitro antiproliferative activities. In Table 1 are summarized the in vitro antiproliferative 
activities of 2-methoxy/ethoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)benzo[b]furan 
derivatives 3a-l against a panel of seven human cancer cell lines, using 1a as reference 
compound. The results presented in Table 1 indicate that inhibition of cell growth was highly 
dependent upon the presence and position of the methoxy substituent on the benzene portion 
of the benzo[b]furan system. In both series of 2-alkoxycabonyl derivatives, the greatest 
activity occurred when the methoxy group was located at the C-6 position (3g and 3h), the 
least when it was located at the C-4 (IC50>10 M) position. In fact, the IC50’s obtained in the 
7 cell lines with the C-6 substituted compounds ranged from 0.3 to 27 (average, 7.8) nM with 
3g and from 13 to 100 (average, 34) nM with 3h. The superiority of the methoxycarbonyl 
substituent over the ethoxycarbonyl substituent was observed in all of the cell lines except the 
MCF-7 cells, which were equally sensitive to both compounds. Overall, compounds 3i 
(average IC50, 370 nM) and 3j (average IC50, 670 nM), with the C-7 methoxy substituent, 
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were more active than 3e (average IC50, 1,500 nM) and 3f (average IC50, 2,900 nM), with the 
C-5 methoxy substituent. For these latter two pairs of compounds, an occasional cell line was 
highly sensitive: RS 4;11 cells had IC50 values of 39 nM with 3e and 1 nM with 3i, and Jurkat 
cells had an IC50 value of 30 nM with 3i. Average IC50 values for the compounds bearing no 
methoxy substituent were 3,300 and 2,600 nM for compounds 3a and 3b, respectively. Thus, 
even the C-5 methoxy substituent improved overall compound activity. Finally, we also 
prepared both the methoxy- and ethoxycarbonyl compounds with a C-7 ethoxy substituent (3k 
and 3l, respectively). With all cell lines, the C-7-ethoxy compound was significantly less 
active than its cognate C-7-methoxy compound. 
The most potent compound identified in this study was the 2-methoxycarbonyl-3-(3’,4’,5’-
trimethoxyanilino)-6-methoxybenzo[b]furan derivative 3g, which was more active than the 
reference compound CA-4 in five of the seven cancer cell lines, while the two compounds had 
similar activity against Jurkat and HL-60 cells. The antiproliferative data obtained with 3g 
may indicate that an anilinic nitrogen with a hydrogen as a proton bonding donor at the C-3 
position of the benzo[b]furan skeleton can be a good surrogate for the carbonyl group in 
compounds with general structure 2.  
In comparing the two series of 2-alkoxycarbonyl derivatives with the methoxy group at the 
same position of the benzo[b]furan nucleus, the 2-methoxycarbonyl derivative generally had 
greater activity than its ethoxycarbonyl counterpart (i.e., 3e vs. 3f, 3g vs. 3h, 3i vs. 3j, 3k vs. 
3l). 
Evaluation of antiproliferative activity in non-cancer cells. We investigated the effects of 
the two most active compounds (3g and 3h) on non-cancer cells. We examined human 
peripheral blood lymphocytes (PBLs) and HUVECs isolated from healthy donors. As shown 
in Table 2, in both unstimulated and mitogen-activated lymphocytes, the two compounds had 
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little toxicity as compared to tumor cells. Somewhat greater toxicity was noted in HUVECs 
incubated with the two compounds, although also in this case the IC50 values were 
substantially higher than those obtained with the tumor cells. Moreover, in contrast to what 
was found with the tumor cells, 3h was more active than 3g in the non-cancer cells. These 
results suggest that 3g and 3h may have a preferential selectivity toward cancer cells.  
Inhibition of tubulin polymerization and colchicine binding. Compounds 3e and 3g-j and 
the reference compound CA-4 were evaluated for inhibitory effects on tubulin polymerization 
and on the binding of [
3
H]colchicine to tubulin for an indication whether their 
antiproliferative effects might be caused by an interaction with microtubules (Table 3).
 26-28
 
The most potent of the compounds examined was 3g, with an assembly IC50 of 1.1 M, the 
same value obtained with CA-4, while 3h was slightly less active than CA-4. This is in 
agreement with 3g being the compound with the greatest antiproliferative activity. 
Compounds 3e, 3i and 3j were 6-7-fold less active than CA-4, with IC50 values of 7.5, 7.6 and 
6.4 M, respectively, which was consistent with their lower antiproliferative activity.  
Colchicine binding studies were performed on the only derivatives (3g and 3h) with tubulin 
assembly IC50 values lower than 5 M. In reaction mixtures containing 1.0 M tubulin and 
5.0 M [3H]colchicine, compound 3g potently inhibited the binding to [3H]colchicine to  
tubulin, with 83% inhibition occurring when 3g and radiolabeled drug were at 5.0 M in the 
reaction mixture. Compound 3g was less potent than 1a, which in these experiments inhibited 
colchicine binding by 99%. Derivative 3h was slightly less potent than 3g, with 74% 
inhibition occurring with the compound at 5.0 M. 
For the most active compounds 3g and 3h, a good correlation was observed between 
antiproliferative activities and inhibition of tubulin polymerization and colchicine binding. 
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These results suggest that these two derivatives act as microtubule-depolymerizing agents 
through an interaction with tubulin at the colchicine site or a site that overlaps the colchicine 
site. 
Molecular modeling. In order to investigate the possible binding mode of these novel 
compounds, a series of molecular docking studies were performed in the colchicine site of 
tubulin. In the binding mode for compound 3g presented in Figure 1, the trimethoxyphenyl 
ring of the compound is in proximity to Cys241. Furthermore, there is a potential hydrogen 
bond between the ester moiety and Ala250, an interaction observed with other colchicine site 
agents.
29
 These results could provide an explanation for the difference in biological activity 
observed for the compounds bearing a substituent in position 4, 5 or 7 of the benzo[b[furan 
(e.g. 3c, 3e and 3i) versus 3g with its 6-methoxy group. Our models indicate that the 
colchicine-binding pocket cannot readily accommodate the compounds with the 4-, 5- or 7-
methoxy substituents. 
Analysis of cell cycle effects. The effects of a 24 h treatment with different concentrations of 
3g or 3h on cell cycle progression was determined by flow cytometry in Jurkat and HeLa cells 
(Figure 2, Panels A and B). The two compounds caused a significant G2/M arrest in a 
concentration-dependent manner in the cell lines tested, with a rise in G2/M cells occurring at 
a concentration as low as 60 nM, while at higher concentrations more than 70% of the cells 
were arrested in G2/M. The cell cycle arrest in G2/M phase was accompanied by a 
comparable reduction in the proportion of cells in both the G1 and S phases of the cell cycle. 
We next studied the association between the induced G2/M arrest by the two compounds and 
alterations in expression of various proteins that regulate cell division. As shown in Figure 2 
(Panel C) in HeLa cells, a 24 h treatment with either compound at 100 nM or 250 nM caused 
a significant increase in cyclin B expression, which, in association with cdc2, controls both 
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entry into and exit from mitosis.
30,31
 After a 48 h treatment, cyclin B expression decreased. 
More importantly, p-cdc2
Tyr15
 expression increased after a 24 h treatment, while at 48 h a 
slight decrease was observed. However, no major changes in the expression of phosphatase 
cdc25c were observed. These results indicate that arrest at G2/M induced by the compounds is 
caused by an increase of cyclin B activity, followed by its accumulation, leading to a decrease 
of p-cdc2
 Tyr15
. The decline in the level of p-cdc2
Tyr15
 at 48 h was
 
more marked at the highest 
concentration (250 nM) examined. 
Compounds 3g and 3h induce apoptosis through the mitochondrial pathway. The mode 
of cell death induced by 3g and 3h was investigated with the annexin-V assay.
32 
As depicted 
in Figure 3 (Panels A and B), HeLa cells treated with 3g or 3h for 24 or 48 h showed an 
accumulation of annexin-V positive cells in comparison with the control, in a concentration 
and time-dependent manner, and this is indicative of the occurrence of apoptosis.  
Since many antimitotic compounds induce apoptosis through the mitochondrial pathway,
33-36
 
we determined whether 3g and 3h induced an alteration of the mitochondrial transmembrane 
potential (mt). mt was monitored by flow cytometry using the dye 5,5’,6,6’-tetrachloro-
1,1’,3,3’-tetraethylbenzimidazolcarbocyanine (JC-1). As shown in Figure 4 (Panel A) in HeLa 
cells, both 3g and 3h induced a time and concentration–dependent increase in the proportion 
of cells with depolarized mitochondria. 
Mitochondrial membrane depolarization is associated with mitochondrial production of 
reactive oxygen species (ROS).
37
 Therefore, we investigated whether ROS production 
increased after treatment with the test compounds. We measured the production of ROS by 
flow cytometry utilizing 2,7-dichlorodihydrofluorescein diacetate (H2-DCFDA). 
As shown in Figure 4 (Panel B), both 3g and 3h induced the production of significant 
amounts of ROS in comparison with control cells, in agreement with the dissipation of mt. 
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Altogether, these results indicate that these compounds induced apoptosis through the 
mitochondrial pathway. 
 
Compounds 3g and 3h induce activation of caspases and down-regulation of the anti-
apoptotic proteins Bcl-2 and Mcl-1. To determine whether compounds 3g and 3h induced 
caspase-dependent cell death, we performed an immunoblot analysis of the activation of 
caspase-9 and caspase-3, two caspases involved in the apoptotic mitochondrial pathway.
 
Exposure of HeLa cells to either compound resulted in the activation of caspase-9 and 
caspase-3 in a time and concentration dependent manner, as shown in Figure 5. Moreover, we 
also observed the cleavage of poly(ADP-ribose) polymerase (PARP), which is one of the main 
cleavage targets of caspase-3, both in vitro and in vivo.
38
  
Many recent studies have shown that regulation of the Bcl-2 family of proteins shares the 
signaling pathways induced by antimicrotubule compounds.
33,34 
Several pro-apoptotic family 
proteins (e.g., Bax, Bid, Bim and Bak) promote the release of cytochrome c, whereas anti-
apoptotic members (Bcl-2, Bcl-XL and Mcl-1) are capable of antagonizing the pro-apoptotic 
proteins and preventing the loss of mitochondrial membrane potential. In agreement with 
these observations, we found that Bcl-2 after a 48 h treatment with either compound was 
reduced, while the expression of Mcl-1, which is another anti-apoptotic member of the Bcl-2 
family, was also strongly down regulated. This change was observed after 48 h treatments at 
both 100 and 250 nM. However, at 24 h we observed an increase in the expression of Mcl-1 
with 3g but not with 3h. 
Altogether, our findings indicate that 3g and 3h are able to down regulate the expression of 
antiapoptotic proteins in line with recent reports that suggest that sensitivity to antimitotic 
drugs is regulated by Mcl-1 levels.
39
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Evaluation of antitumor activity of compound 3g in vivo. To determine the in vivo 
antitumor activity of 3g, a syngeneic hepatocellular carcinoma model in mice was used.
40
 In 
preliminary experiments in vitro, we had determined that both compound 3g and CA-4, used 
as reference compound, showed potent cytotoxic activity (3g, IC50=1.2±0.6 nM; CA-4, 
IC50=0.9±0.5 nM) against BNL 1ME A.7R.1 cells. Tumors were established by subcutaneous 
injection of BNL 1ME A.7R.1 cells into the backs of Balb/c mice. Once the tumor reached a 
measurable size (about 100 mm
3
), twenty mice were randomly assigned to one of four groups. 
In two of the groups, compound 3g was injected intraperitoneally at doses of 5 and 10 mg/kg, 
respectively. In a third group, CA-4P was injected at 5 mg/kg, while the fourth group was 
used as a control. As shown in Figure 6 (Panel A), compound 3g caused a significant 
reduction in tumor growth (44.5%), as compared with administration of vehicle, at the dose of 
10 mg/kg but not at 5 mg/kg. At the lower dose the growth inhibition shown in the figure did 
not reach statistical significance. The effect of 5 mg/kg of CA-4P was not substantially 
different from that of 10 mg/kg of 3g, and the CA-4P effect was significant relative to the 
control. During the treatment period, only a small decrease in body weight occurred in the 
animals treated with 3g at the higher concentration (Figure 6, Panel B).  
Derivative 3g has antivascular effects in vitro and in vivo. Recent antitumor strategies have 
included the use of chemotherapeutics with antiangiogenic or antivascular drugs to increase 
the efficacy of the treatment.
12
 Many tubulin binding agents show antivascular effects against 
tumor endothelium,
12 
including CA-4, and for that reason we evaluated 3g for its effects on 
endothelial cells in vitro. We used HUVECs as a model to study angiogenesis in vitro. 
Endothelial cell migration to the tumor site is an important mechanism of angiogenesis,
41
 and 
the inhibition of this process is a valuable strategy to arrest the development of tumor 
vasculature. With this aim, we evaluated endothelial cell motility by scratching a HUVEC 
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monolayer and monitoring the ability of cells to reclose the wound. As shown in Figure 7 
(Panels A and B), 3g was very efficient in arresting cell motility. The effect was statistically 
significant with only a 6 h incubation at 25 nM and became highly significant for all the tested 
concentrations after 24 h, even with only 5 nM 3g. 
To further evaluate the antivascular activity of 3g, we analyzed the ability of the compound to 
disrupt the “tubule-like” structures formed by HUVECs seeded on Matrigel. Matrigel is an 
extracellular matrix rich in pro-angiogenic factors that stimulate single endothelial cells to 
assume an extended shape and produce a reticulum similar to a capillary network. 
As shown in Figure 7 (Panels C-E), after a 1 h (Panels C and D) or 3 h (Panel E) incubation, 
the compound clearly disrupted the network of HUVECs, as compared with the control. After 
3 h, all the tested concentrations were effective in altering the tubule-like structures (Figure 7, 
Panel C). Image analysis
42
 was performed to obtain a quantitative measurement of the total 
length of the tubules, the area and the number of meshes, the percent of area covered by 
HUVECs, and the number of branching points after both a 1 h (Figure 7, Panel D) and 3 h 
(Figure 7, Panel E) treatment. It is important to stress that 3g exerted its antivascular effects in 
vitro at concentrations that did not affect HUVEC proliferation (see Table 2).  
The antivascular activity of 3g was also investigated in vivo. First, we used the chick embryo 
chorioallantoic membrane (CAM), which is a highly vascularized structure, as a model. 
Through alginate beads applied on the CAM, 3g (1-100 pmol/egg) was slowly distributed 
within the membrane, starting from day 11 post egg fertilization, in the presence or absence of 
fibroblast growth factor (FGF) (100 ng/egg), a vascular growth factor. As shown in Figure 8 
(Panel A), 3g alone, at the highest concentration (100 pmol/egg) used, did not induce blood 
vessels to increase in number. On the other hand, treatment with FGF gave rise to an 
extensive production of blood vessels, and this increase was strongly reduced by 3g treatment, 
even at the lowest tested concentration (1 pmol/egg). 
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3g was further evaluated in a murine tumor model. BL6-B16 mouse melanoma cells, injected 
subcutaneously in syngeneic C57/BL6 mice, proliferate and generate tumor masses. After a 24 
h treatment with 3g at 30 mg/kg i.p., the tumor was excised and the blood vessels stained with 
an antibody against the endothelial marker CD31 and counted. As shown in Figure 8 (Panel 
B), the number and, especially, the size of the vessels were reduced. This reduction in number 
was about 20% and was statistically significant (Panel C, P < 0.05). Altogether our results 
indicate that 3g is endowed with vascular disrupting properties both in vitro and in vivo. In 
addition, we also observed that the effects on endothelial cells induced by 3g were similar to 
those observed after CA-4 treatment under the same experimental conditions, as described 
previously.
43
  
Conclusions 
In conclusion, we demonstrated that the bioisosteric replacement of the carbonyl bridge 
between the C-3 position of the benzo[b]furan ring and the 3,4,5-trimethoxyphenyl moiety by 
an anilinic nitrogen resulted in highly bioactive antimitotic agents based on the 2-
alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)benzo[b]furan molecular skeleton. Compounds 
3g and 3h were prepared by an efficient two-step synthetic procedure, and both compounds 
showed activity comparable with that of CA-4. Our structure-activity relationship studies 
involved placing the electron-donating methoxy substituent at the C-4, C-5, C-6 or C-7 
position on the benzo[b]furan ring. For both the series of alkoxycarbonyl derivatives, 
compounds 3c and 3d with the methoxy group at the C-4 position were inactive, and a 
substantial improvement in antiproliferative activity occurred with the methoxy group at the 
C-5 position (3e and 3f). Simply moving the methoxy group to C-6 resulted in the highly 
active compounds 3g and 3h, while moving the methoxy to C-7 (3i and 3j) resulted in a 
drastic reduction in activity. The 2-methoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)-6-
methoxybenzo[b]furan derivative 3g had the greatest antiproliferative IC50 values, ranging 
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from 0.3 to 27 nM against the seven cancer cell lines we examined. Compound 3g was also a 
potent inhibitor of tubulin assembly, with an IC50 of 1.1 M, similar to that of CA-4. 
Nevertheless, this compound was less active than CA-4 as an inhibitor of the binding of 
[
3
H]colchicine to tubulin, with 83% and 99% inhibition, respectively. Compound 3g, in vitro 
was able to induce mitotic arrest followed by apoptosis through mitochondrial depolarization 
and activation of both caspase-9 and -3. Importantly, it exhibited significant antitumor activity 
in vivo and interesting antivascular properties. Thus, 3g is a promising new tubulin binding 
agent with potential as an antitumor and antivascular agent that could improve common 
anticancer therapies. 
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Experimental Section 
Chemistry. Materials and methods. 
1
H NMR and 
13
C NMR spectra were recorded in CDCl3 
solution with a Varian Mercury Plus 400 spectrometer at 400 MHz and 100 MHz, 
respectively. Peak positions are given in parts per million () downfield from 
tetramethylsilane as internal standard, and J values are given in hertz. Positive-ion 
electrospray ionization (ESI) mass spectra were measured on a double-focusing Finnigan 
MAT 95 instrument with BE geometry. High resolution mass spectroscopic (HRMS) 
measurements were performed using an ESI-Q-TOF mass spectrometer (Agilent 
Technologies). Analytical HPLC analyses were performed at ambient temperature on a 
Beckman 125 liquid chromatograph fitted with a Luna C-18 column (4.6 x 100 mm, 3 μm 
particle size) with 0.1% TFA in H2O (A) and 0.1% TFA in CH3CN (B) solvent mixtures and 
equipped with a Beckman 168 diode array detector. Melting points (mp) were determined on a 
Buchi-Tottoli apparatus and are uncorrected. The purity of tested compounds was determined 
by combustion elemental analyses conducted by the Microanalytical Laboratory of the 
Chemistry Department of the University of Ferrara with a Yanagimoto MT-5 CHN recorder 
elemental analyzer. All tested compounds yielded data consistent with a purity of at least 95% 
as compared with the theoretical values. All reactions were carried out under an inert 
atmosphere of dry nitrogen, unless otherwise indicated. TLC was performed on silica gel 
(precoated F254 Merck plates), and compounds were visualized with aqueous KMnO4. Flash 
column chromatography was performed using 230-400 mesh silica gel and the indicated 
solvent system. Organic solutions were dried over anhydrous Na2SO4. All commercial 
chemicals and solvents were reagent grade and were used without further treatment. 
General procedure A for the synthesis of compounds 5a-l. A suspension of the appropriate 
2-hydroxybenzonitrile 4a-f (5 mmol), methyl/ethylbromoacetate (6 mmol, 1.2 equiv.) and 
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K2CO3 (1.38 g., 10 mmol, 2 equiv.) in DMF (10 mL) was stirred at 60 °C for 4 h until 
consumption of the limiting reagent, followed by reflux heating for 8 h. The reaction mixture 
was cooled to ambient temperature and filtered through Celite, then the filtrate was 
evaporated in vacuo. The residue was dissolved with ethyl acetate (30 mL), and the solution 
was washed sequentially with water (10 mL) and brine (10 mL). The organic layer was dried, 
filtered and concentrated under reduced pressure, and the residue was purified by flash 
column chromatography on silica gel.  
Methyl 3-amino-benzofuran-2-carboxylate (5a). Following general procedure A, the crude 
residue was purified by flash chromatography, using ethyl acetate:petroleum ether 2:8 (v:v) as 
eluent, to furnish 5a as a yellow solid. Yield: 78%, mp 95-96 °C.
 1
H-NMR (CDCl3) : 3.97 (s, 
3H), 4.99 (bs, 2H), 7.24 (m, 1H), 7.46 (m, 2H), 7.56 (dd, J=7.8 and 1.0 Hz, 1H). MS (ESI): 
[M]
+
=191.5.  
Ethyl 3-amino-benzofuran-2-carboxylate (5b). Following general procedure A, the crude 
residue was purified by flash chromatography, using ethyl acetate:petroleum ether 2:8 (v:v) as 
eluent, to furnish 5b as a green solid. Yield: 72%, mp 83-84 °C.
 1
H-NMR (CDCl3) : 1.40 (t, 
J=7.2 Hz, 3H), 4.46 (q, J=7:2 Hz, 2H), 4.97 (bs, 2H), 7.24 (m, 1H), 7.46 (m, 2H), 7.57 (dd, 
J=7.8 and 1.0 Hz, 1H). MS (ESI): [M+1]
+
=206.1. 
Methyl 3-amino-4-methoxybenzofuran-2-carboxylate (5c). Following general procedure A, 
the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 
3:7 (v:v) as eluent, to furnish 5c as a white solid. Yield: 75%, mp 148-149 °C.
 1
H-NMR 
(CDCl3) : 3.94 (s, 3H), 3.96 (s, 3H), 5.40 (bs, 2H), 6.58 (d, J=7.8 Hz, 1H), 6.99 (d, J=8.4 Hz, 
1H), 7.54 (t, J=8.4 Hz, 1H). MS (ESI): [M+1]
+
=221.2. 
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Ethyl 3-amino-4-methoxybenzofuran-2-carboxylate (5d). Following general procedure A, 
the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 
3:7 (v:v) as eluent, to furnish 5d as a colorless oil. Yield: 58%.
 1
H-NMR (CDCl3) : 1.42 (t, 
J=7.2 Hz, 3H), 3.95 (s, 3H), 4.38 (q, J=7.2 Hz, 2H), 5.42 (bs, 2H), 6.55 (d, J=8.2 Hz, 1H), 
7.04 (d, J=8.6 Hz, 1H), 7.32 (t, J=8.6 Hz, 1H). MS (ESI): [M+1]
+
=236.3. 
Methyl 3-amino-5-methoxy-benzofuran-2-carboxylate (5e). Following general procedure 
A, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum 
ether 4:6 (v:v) as eluent, to furnish 5e as a brown solid. Yield: 63%, mp 163-165 °C.
 1
H-NMR 
(CDCl3) : 3.86 (s, 3H), 3.96 (s, 3H), 4.90 (bs, 2H), 6.92 (d, J=2.4 Hz, 1H), 7.06 (dd, J=9.2 
and 2.4 Hz, 1H), 7.61 (d, J=9.2 Hz, 1H). MS (ESI): [M+1]
+
=222.2. 
Ethyl 3-amino-5-methoxy-benzofuran-2-carboxylate (5f). Following general procedure A, 
the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 
3:7 (v:v) as eluent, to furnish 5f as a yellow solid. Yield: 53%, mp 151-153 °C.
 1
H-NMR 
(CDCl3) : 1.43 (t, J=7.0 Hz, 3H), 3.86 (s, 3H), 4.45 (q, J=7.0 Hz, 2H), 4.89 (bs, 2H), 6.92 (d, 
J=2.4 Hz, 1H), 7.05 (dd, J=9.0 and 2.4 Hz, 1H), 7.33 (d, J=9.0 Hz, 1H). MS (ESI): 
[M+1]
+
=236.2. 
Methyl 3-amino-6-methoxybenzofuran-2-carboxylate (5g). Following general procedure 
A, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum 
ether 3:7 (v:v) as eluent, to furnish 5g as a cream colored solid. Yield: 73%, mp 150-151 °C.
 
1
H-NMR (CDCl3) 3.84 (s, 3H), 3.94 (s, 3H), 4.97 (bs, 2H), 6.83 (dd, J=8.6 and 2.2 Hz, 1H), 
6.91 (d, J=2.2 Hz, 1H), 7.39 (d, J=8.6 Hz, 1H). MS (ESI): [M+1]
+
=222.1. 
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Ethyl 3-amino-6-methoxybenzofuran-2-carboxylate (5h). Following general procedure A, 
the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 
3:7 (v:v) as eluent, to furnish 5h as a yellow solid. Yield: 52%, mp 145-147 °C.
 1
H-NMR (d6-
DMSO) 1.43 (t, J=7.0 Hz, 3H), 3.85 (s, 3H), 4.40 (q, J=7.0 Hz, 2H), 4.95 (bs, 2H), 6.85 (dd, 
J=8.8 and 2.2 Hz, 1H), 6.93 (d, J=2.2 Hz, 1H), 7.43 (d, J=8.8 Hz, 1H). MS (ESI): 
[M+1]
+
=236.2. 
Methyl 3-amino-7-methoxybenzofuran-2-carboxylate (5i). Following general procedure A, 
the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 
3:7 (v:v) as eluent, to furnish 5i as a brown solid. Yield: 61%, mp 149-151 °C.
 1
H-NMR 
(CDCl3) 3.94 (s, 3H), 3.98 (s, 3H), 4.96 (bs, 2H), 6.91 (dd, J=7.0 and 2.0 Hz, 1H), 7.14 (m, 
2H). MS (ESI): [M+1]
+
=222.1. 
Ethyl 3-amino-7-methoxybenzofuran-2-carboxylate (5j). Following general procedure A, 
the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 
3:7 (v:v) as eluent, to furnish 5j as a yellow solid. Yield: 78%, mp 123-125 °C.
 1
H-NMR 
(CDCl3) 1.42 (t, J=7.0 Hz, 3H), 3.99 (s, 3H), 4.40 (q, J=7.0 Hz, 2H), 4.95 (bs, 2H), 6.90 (dd, 
J=6.8 and 1.8 Hz, 1H), 7.13 (m, 2H). MS (ESI): [M+1]
+
=236.2. 
Methyl 3-amino-7-ethoxybenzofuran-2-carboxylate (5k). Following general procedure A, 
the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 
3:7 (v:v) as eluent, to furnish 5k as a yellow solid. Yield: 58%, mp 139-141 °C.
 1
H-NMR 
(CDCl3) 1.50 (t, J=7.2 Hz, 3H), 3.94 (s, 3H), 4.21 (q, J=7.2 Hz, 2H), 4.95 (bs, 2H), 6.91 (dd, 
J=6.8 and 2.2 Hz, 1H), 7.12 (m, 2H). MS (ESI): [M+1]
+
=236.3. 
Ethyl 3-amino-7-ethoxybenzofuran-2-carboxylate (5l). Following general procedure A, the 
crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 3:7 
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(v:v) as eluent, to furnish 5l as a yellow solid. Yield: 62%, mp 112-114 °C.
 1
H-NMR (CDCl3) 
1.42 (t, J=7.2 Hz, 3H), 1.51 (t, J=7.0 Hz, 3H), 4.26 (q, J=7.2 Hz, 2H), 4.41 (q, J=7.0 Hz, 2H), 
4.93 (bs, 2H), 6.94 (dd, J=7.0 and 2.2 Hz, 1H), 7.12 (m, 2H). MS (ESI): [M+1]
+
=250.3. 
General procedure B for the preparation of compounds 3a-l. To a dry Schlenk tube, dry 
toluene (5 mL), 3-aminobenzofuran derivative 5a-l (0.5 mmol), Pd(OAc)2 (6 mol%, 30 mg), 
rac-BINAP (4 mol%, 30 mg), CsCO3 (230 mg, 0.7 mmol, 1.4 equiv.) and 5-bromo-1,2,3-
trimethoxybenzene (148 mg, 0.6 mmol, 1.2 equiv.) were added under Ar, and the mixture was 
heated with stirring at 120 °C for 18 h. Upon cooling, ethyl acetate was added (5 mL), the 
mixture was filtered through Celite under vacuum and the filtrate diluted with ethyl acetate 
(10 mL) and water (5 mL). The aqueous phase was separated and further extracted with ethyl 
acetate (2x5 mL). The combined organic phases were washed with brine (5 mL), dried, 
concentrated under reduced pressure and yielded a residue that was purified by flash column 
chromatography on silica gel.  
Methyl 3-[(3,4,5-trimethoxyphenyl)amino]-benzofuran-2-carboxylate (3a). Following 
general procedure B, the crude residue was purified by flash chromatography, using ethyl 
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3a as a yellow solid. Yield: 67%, mp 
176-178 °C.
 1
H-NMR (CDCl3) : 3.77 (s, 6H), 3.87 (s, 3H), 4.00 (s, 3H), 6.42 (s, 2H), 7.05 
(m, 1H), 7.34 (d, J=7.8 Hz, 1H), 7.48 (m, 2H), 7.74 (s, 1H). 
13
C-NMR (CDCl3) : 51.9, 56.2 
(2x), 61.2, 99.6 (2x), 112.8, 117.8, 120.9, 122.1, 123.6, 123.8, 128.8, 136.8, 137.1, 153.6 (2x), 
154.6, 157.3. MS (ESI): [M+1]
+
=357.9. Anal. (C19H19NO6) C, H, N. 
Ethyl 3-[(3,4,5-trimethoxyphenyl)amino]-benzofuran-2-carboxylate (3b). Following 
general procedure B, the crude residue was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3b as a yellow solid. Yield: 56%, mp 
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122-124 °C.
 1
H-NMR (CDCl3) : 1.46 (t, J=7.0 Hz, 3H), 3.77 (s, 6H), 3.86 (s, 3H), 4.45 (q, 
J=7.0 Hz, 2H), 6.41 (s, 2H), 7.12 (m, 1H), 7.32 (d, J=7.8 Hz, 1H), 7.54 (m, 2H), 7.80 (s, 1H). 
13
C-NMR (CDCl3) : 14.6, 56.1 (2x), 60.8, 61.1, 99.4 (2x), 109.9, 112.8, 117.8, 120.9, 121.9, 
123.5, 128.6, 136.5, 126.8, 153.5 (2x), 154.4, 158.1. MS (ESI): [M+1]
+
=372.4. Anal. 
(C20H21NO6) C, H, N. 
Methyl 3-(3,4,5-trimethoxyphenylamino)-4-methoxybenzofuran-2-carboxylate (3c). 
Following general procedure B, the crude residue was purified by flash chromatography, using 
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3c as a white solid. Yield: 63%, 
mp 171-172 °C.
 1
H-NMR (CDCl3) : 3.66 (s, 6H), 3.78 (s, 3H), 3.84 (s, 3H), 3.91 (s, 3H), 
6.38 (s, 2H), 7.02 (dd, J=8.6 and 2.0 Hz, 1H), 7.32 (d, J=2.0 Hz, 1H), 7.48 (d, J=8.6 Hz, 1H), 
7.77 (s, 1H). 
13
C-NMR (CDCl3) : 51.8, 53.2, 56.8 (2x), 60.9, 99.6 (2x), 105.2, 105.9, 107.2, 
119.4, 124.6, 127.7, 135.1, 135.8, 153.6 (2x), 155.8, 155.9, 163.3. MS (ESI): [M+1]
+
=388.2. 
Anal. (C20H21NO7) C, H, N. 
Ethyl 3-(3,4,5-trimethoxyphenylamino)-4-methoxybenzofuran-2-carboxylate (3d). 
Following general procedure B, the crude residue was purified by flash chromatography, using 
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3d as a yellow solid. Yield: 61%, 
mp 83-85 °C.
 1
H-NMR (CDCl3) : 1.44 (t, J=7.2 Hz, 3H), 3.68 (s, 6H), 3.76 (s, 3H), 3.94 (s, 
3H), 4.32 (q, J=7.2 Hz, 2H), 6.32 (s, 2H), 6.49 (d, J=8.2 Hz, 1H), 6.95 (d, J=8.6 Hz, 1H), 7.34 
(t, J=8.6 Hz, 1H), 7.77 (s, 1H). 
13
C-NMR (CDCl3) : 14.4, 51.8, 53.3, 56.7 (2x), 99.6 (2x), 
104.5, 105.2, 105.7, 107.0, 118.8, 124.5, 127.9, 135.0, 135.6, 153.8 (2x), 155.9, 160.0, 163.8. 
MS (ESI): [M+1]
+
=402.2. Anal. (C21H23NO7) C, H, N. 
Methyl 3-(3,4,5-trimethoxyphenylamino)-5-methoxybenzofuran-2-carboxylate (3e). 
Following general procedure B, the crude residue was purified by flash chromatography, using 
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ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3e as a yellow solid. Yield: 53% 
yield, mp 140-142 °C.
 1
H-NMR (CDCl3) : 3.65 (s, 3H), 3.79 (s, 6H), 3.86 (s, 3H), 3.99 (s, 
3H), 6.48 (s, 2H), 6.68 (d, J=2.8 Hz, 1H), 7.07 (dd, J=9.0 and 2.8 Hz, 1H), 7.42 (d, J=9.0 Hz, 
1H), 7.78 (s, 1H). 
13
C-NMR (CDCl3) : 51.9, 55.9, 56.2 (2x), 61.2, 99.3 (2x), 104.5, 112.8, 
113.5, 113.8, 116.5, 118.9, 132.2, 132.6, 135.8, 136.9, 153.6 (2x), 158.2. MS (ESI): 
[M+1]
+
=388.0. Anal. (C20H21NO7) C, H, N. 
Ethyl 3-(3,4,5-trimethoxyphenylamino)-5-methoxybenzofuran-2-carboxylate (3f). 
Following general procedure B, the crude residue was purified by flash chromatography, using 
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3f as a yellow solid. Yield: 56% 
yield, mp 105-107 °C.
 1
H-NMR (CDCl3) : 1.46 (t, J=7.0 Hz, 3H), 3.65 (s, 3H), 3.79 (s, 6H), 
3.86 (s, 3H), 4.44 (q, J=7.0 Hz, 2H), 6.40 (s, 2H), 6.69 (d, J=2.8 Hz, 1H), 7.07 (dd, J=9.2 and 
2.8 Hz, 1H), 7.43 (d, J=9.2 Hz, 1H), 7.70 (s, 1H). 
13
C-NMR (CDCl3) : 14.7, 55.9, 55.2 (2x), 
60.9, 61.2, 99.1 (2x), 104.5, 113.6, 118.8, 121.3, 128.9, 134.4, 136.4, 137.0, 149.6, 153.6 
(2x), 154.9, 161.9. MS (ESI): [M+1]
+
=402.2. Anal. (C21H23NO7) C, H, N.  
Methyl 3-(3,4,5-trimethoxyphenylamino)-6-methoxybenzofuran-2-carboxylate (3g). 
Following general procedure B, the crude residue was purified by flash chromatography, using 
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3g as a yellow solid. Yield: 78%, 
mp 143-145 °C.
 1
H-NMR (CDCl3) : 3.78 (s, 6H), 3.85 (s, 3H), 3.86 (s, 3H), 3.97 (s, 3H), 
6.42 (s, 2H), 6.71 (dd, J=8.8 and 1.8 Hz, 1H), 6.94 (d, J=1.8 Hz, 1H), 7.18 (d, J=8.8 Hz, 1H), 
7.72 (s, 1H). 
13
C-NMR (CDCl3) : 51.7, 55.7, 56.2 (2x), 61.2, 95.8, 99.7 (2x), 112.3, 114.1, 
120.1, 124.1, 136.5, 136.9, 153.6 (2x), 155.8, 156.1, 160.3, 161.3. MS (ESI): [M+1]
+
=388.0. 
Anal. (C20H21NO7) C, H, N. HRMS calculated for C20H21NO7 (M+H)
+
, 388.1391; found, 
388.13909. 
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Ethyl 3-(3,4,5-trimethoxyphenylamino)-6-methoxybenzofuran-2-carboxylate (3h). 
Following general procedure B, the crude residue was purified by flash chromatography, using 
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3h as a yellow solid. Yield: 57%, 
mp 110-112 °C.
 1
H-NMR (CDCl3) : 1.45 (t, J=6.8 Hz, 3H), 3.78 (s, 6H), 3.80 (s, 3H), 3.86 
(s, 3H), 4.43 (q, J=6.8 Hz, 2H), 6.42 (s, 2H), 6.70 (dd, J=8.8 and 2.2 Hz, 1H), 6.96 (d, J=2.2 
Hz, 1H), 7.19 (d, J=8.8 Hz, 1H), 7.77 (s, 1H). 
13
C-NMR (CDCl3) : 14.7, 55.7, 56.2 (2x), 
60.7, 61.2, 95.9, 99.5 (2x), 112.2, 113.1, 124.0, 125.9, 127.7, 136.6, 140.0, 153.6 (2x), 
154.01, 156.2, 161.2. MS (ESI): [M+1]
+
=402.2. Anal. (C21H23NO7) C, H, N. HRMS 
calculated for C21H23NO7 (M+H)
+
, 402.1547; found, 402.1546. 
Methyl 3-(3,4,5-trimethoxyphenylamino)-7-methoxybenzofuran-2-carboxylate (3i). 
Following general procedure B, the crude residue was purified by flash chromatography, using 
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3i as a yellow solid. Yield: 68%, 
mp 177-179 °C.
 1
H-NMR (CDCl3) : 3.77 (s, 6H), 3.86 (s, 3H), 3.97 (s, 3H), 4.00 (s, 3H), 
6.40 (s, 2H), 6.92 (m, 2H), 6.99 (m, 1H), 7.72 (s, 1H). 
13
C-NMR (CDCl3) : 51.7, 55.9, 56.1 
(2x), 61.2, 99.5 (2x), 109.4, 115.4, 121.0, 122.5, 122.7, 124.5, 136.8, 139.1, 146.2, 147.1, 
153.6 (2x), 162.3. MS (ESI): [M+1]
+
=388.2. Anal. (C20H21NO7) C, H, N. 
Ethyl 3-(3,4,5-trimethoxyphenylamino)-7-methoxybenzofuran-2-carboxylate (3j). 
Following general procedure B, the crude residue was purified by flash chromatography, using 
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3j as a white solid. Yield: 73%, 
mp 184-186 °C.
 1
H-NMR (CDCl3) : 1.47 (t, J=7.0 Hz, 3H), 3.77 (s, 6H), 3.86 (s, 3H), 4.00 
(s, 3H), 4.47 (q, J=7.0 Hz, 2H), 6.40 (s, 2H), 6.91 (m, 2H), 6.99 (m, 1H), 7.78 (s, 1H). 
13
C-
NMR (CDCl3) : 14.7, 56.0, 56.1 (2x), 60.8, 61.2, 99.3 (2x), 106.5, 108.6, 109.3, 110.5, 
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115.4, 122.7, 124.5, 135.9, 137.0, 149.5, 153.6 (2x), 161.5. MS (ESI): [M+1]
+
=402.2. Anal. 
(C21H23NO7) C, H, N.  
Methyl 3-(3,4,5-trimethoxyphenylamino)-7-ethoxybenzofuran-2-carboxylate (3k). 
Following general procedure B, the crude residue was purified by flash chromatography, using 
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3k as a yellow solid. Yield: 73%, 
mp 135-137 °C.
 1
H-NMR (CDCl3) : 1.52 (t, J=7.0 Hz, 3H), 3.77 (s, 6H), 3.86 (s, 3H), 3.98 
(s, 3H), 4.24 (q, J=7.0 Hz, 2H), 6.40 (s, 2H), 6.88 (m, 2H), 6.97 (m, 1H), 7.71 (s, 1H). 
13
C-
NMR (CDCl3) : 14.8, 51.6, 56.0 (2x), 61.1, 64.5, 99.3 (2x), 109.2, 110.4, 115.1, 118.2, 
122.4, 122.6, 134.5, 136.8, 144.6, 145.4, 153.5 (2x), 162.2. MS (ESI): [M+1]
+
=402.0. Anal. 
(C21H23NO7) C, H, N.  
Ethyl 3-(3,4,5-trimethoxyphenylamino)-7-ethoxybenzofuran-2-carboxylate (3l). 
Following general procedure B, the crude residue was purified by flash chromatography, using 
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3l as a yellow solid. Yield: 52%, 
mp 149-151 °C.
 1
H-NMR (CDCl3) : 1.41 (t, J=7.2 Hz, 3H), 1.53 (t, J=7.0 Hz, 3H), 3.77 (s, 
6H), 3.85 (s, 3H), 4.24 (q, J=7.2 Hz, 2H), 4.44 (q, J=7.0 Hz, 2H), 6.40 (s, 2H), 6.90 (m, 2H), 
6.97 (m, 1H), 7.75 (s, 1H). 
13
C-NMR (CDCl3) : 14.6, 14.8, 56.0 (2x), 60.7, 61.1, 64.5, 99.21 
(2x), 108.8, 110.4, 115.1, 122.6, 123.5, 133.9, 134.1, 136.7, 136.9, 139.9, 153.5 (2x), 175.3. 
MS (ESI): [M+1]
+
=416.2. Anal. (C22H25NO7) C, H, N.  
Molecular modeling. All molecular docking studies were performed on a MacPro dual 
2.66GHz Xeon running Ubuntu 12.04. The simulations were carried out using two tubulin 
structures (http://www.rcsb.org/-PDB code: 1SA0;
44
 PDB code: 3HKC
45
).
 
Hydrogen atoms 
were added to the protein, using the Protonate 3D routine of the Molecular Operating 
Environment (MOE).
46
 Ligand structures were built with MOE and minimized using the 
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MMFF94x forcefield until a RMSD gradient of 0.05 kcal mol
-1
 Å
-1
 was reached. The docking 
simulations were performed using PLANTS.
47
 The docking results obtained using the two 
different protein structures were equivalent. 
Antiproliferative assays. Human T-cell leukemia (Jurkat), human B-cell leukemia (RS4;11) 
and human promyelocytic leukemia (HL-60) cells were grown in RPMI-1640 medium, 
(Gibco, Milano, Italy). Breast adenocarcinoma (MCF-7), human non-small cell lung 
carcinoma (A549), human cervix carcinoma (HeLa) and human colon adenocarcinoma (HT-
29) cells were grown in DMEM medium (Gibco, Milano, Italy). Both media were 
supplemented with 115 units/mL of penicillin G (Gibco, Milano, Italy), 115 g/mL of 
streptomycin (Invitrogen, Milano, Italy) and 10% fetal bovine serum (Invitrogen, Milano, 
Italy). These cell lines were purchased from ATCC. Stock solutions (10 mM) of the different 
compounds were obtained by dissolving them in dimethyl sulfoxide (DMSO). Individual 
wells of a 96-well tissue culture microtiter plate were inoculated with 100 L of complete 
medium containing 8x10
3 
cells. The plates were incubated at 37 °C in a humidified 5% CO2 
incubator for 18 h prior to the experiments. After medium removal, 100 L of fresh medium 
containing the test compound at different concentrations was added to each well and 
incubated at 37 °C for 72 h. The percentage of DMSO in the medium never exceeded 0.25%. 
This was also the maximum DMSO concentration in all cell-based assays described below. 
Cell viability was assayed by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide test as previously described.
36 
The IC50 was defined as the compound concentration 
required to inhibit cell proliferation by 50%, in comparison with cells treated with the 
maximum amount of DMSO, which was considered 100% viability. 
PBLs from healthy donors were obtained by separation on Lymphoprep (Fresenius KABI 
Norge AS) gradient. After extensive washing, cells were resuspended (1.0 x 10
6
 cells/mL) in 
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RPMI-1640 with 10% fetal bovine serum and incubated overnight. For cytotoxicity 
evaluations in proliferating PBL cultures, non-adherent cells were resuspended at 5 x 10
5
 
cells/mL in growth medium containing 2.5 µg/mL PHA (Irvine Scientific). Different 
concentrations of the test compounds were added, and viability was determined 72 h later by 
the MTT test. For cytotoxicity evaluations in resting PBL cultures, non-adherent cells were 
resuspended (5 x 10
5
 cells/mL) and treated for 72 h with the test compounds, as described 
above.  
Effects on tubulin polymerization and on colchicine binding to tubulin. To evaluate the 
effect of the compounds on tubulin assembly in vitro,
26
 varying concentrations of compounds 
were preincubated with 10 M bovine brain tubulin in glutamate buffer at 30 ˚C and then 
cooled to 0 ˚C. After addition of 0.4 mM GTP (final concentration), the mixtures were 
transferred to 0 C cuvettes in a recording spectrophotometer and warmed to 30 °C. Tubulin 
assembly was followed turbidimetrically at 350 nm. The IC50 was defined as the compound 
concentration that inhibited the extent of assembly by 50% after a 20 min incubation. The 
ability of the test compounds to inhibit colchicine binding to tubulin was measured as 
described,
28
 except that the reaction mixtures contained 1 M tubulin, 5 M [3H]colchicine 
and 5 M test compound. 
Flow cytometric analysis of cell cycle distribution. 5 × 10
5
 HeLa or Jurkat cells were 
treated with different concentrations of the test compounds for 24 h. After the incubation 
period, the cells were collected, centrifuged, and fixed with ice-cold ethanol (70%). The cells 
were then treated with lysis buffer containing RNase A and 0.1% Triton X-100 and then 
stained with propidium iodide (PI). Samples were analyzed on a Cytomic FC500 flow 
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cytometer (Beckman Coulter). DNA histograms were analyzed using MultiCycle for 
Windows (Phoenix Flow Systems). 
Apoptosis assay. Cell death was determined by flow cytometry of cells double stained with 
annexin V/FITC and PI. The Coulter Cytomics FC500 (Beckman Coulter) was used to 
measure the surface exposure of phosphatidylserine on apoptotic cells according to the 
manufacturer’s instructions (Annexin-V Fluos, Roche Diagnostics). 
Assessment of mitochondrial changes. The mitochondrial membrane potential was 
measured with the lipophilic cationic dye JC-1 (Molecular Probes), as described.
48
 The 
production of ROS was measured by flow cytometry using H2DCFDA (Molecular Probes), as 
previously described.
48
 
Western blot analysis. HeLa cells were incubated in the presence of 3g or 3h and, after 
different times, were collected, centrifuged, and washed two times with ice cold phosphate 
buffered saline (PBS). The pellet was then resuspended in lysis buffer. After the cells were 
lysed on ice for 30 min, lysates were centrifuged at 15000 x g at 4 °C for 10 min. The protein 
concentration in the supernatant was determined using the BCA protein assay reagents 
(Pierce, Italy). Equal amounts of protein (10 μg) were resolved using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (7.5-15% acrylamide gels) and transferred to PVDF 
Hybond-P membrane (GE Healthcare). Membranes were blocked with a 5% bovine serum 
albumin solution in Tween PBS, the membranes being gently rotated overnight at 4 °C. 
Membranes were then incubated with primary antibodies against Bcl-2, PARP, cleaved 
caspase-9, cdc25c (Cell Signaling), caspase-3 (Alexis), H2AX (Cell Signaling), p53 (Cell 
Signaling), cyclin B (Cell Signaling), p-cdc2
Tyr15
 (Cell Signaling), Mcl-1 (Cell Signaling), or 
β-actin (Sigma-Aldrich) for 2 h at room temperature. Membranes were next incubated with 
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peroxidase labeled secondary antibodies for 60 min. All membranes were visualized using 
ECL Select (GE Healthcare) and exposed to Hyperfilm MP (GE Healthcare). To confirm 
equal protein loading, each membrane was stripped and reprobed with anti-β-actin antibody. 
Evaluation of antivascular activity in vitro. HUVECs were prepared from human umbilical 
cord veins, as previously described.
43
 The adherent cells were maintained in M200 medium 
supplemented with Low Serum Growth Supplement, containing fetal bovine serum, 
hydrocortisone, hEGF, bFGF, heparin, gentamycin/amphotericin (Life Technologies, Monza, 
Italy). Once confluent, the cells were detached by treatment with a trypsin–EDTA solution 
and used in experiments from the first to sixth passages. 
The motility assay for HUVECs was based on “scratch” wounding of a confluent 
monolayer.
49
 Briefly, HUVECs (1x10
5
) were seeded onto 0.1% collagen type I (BD 
Biosciences, Italy)-coated six well plates in complete medium until a confluent monolayer 
was formed. The cells were wounded using a pipette tip, and wells were washed with PBS to 
remove the detached cells. Then, the cells were treated with the test compounds, and, at 
different times from the scratch, the cells were photographed under a light microscope. At all 
indicated time points, the wound width was measured in four areas and compared with the 
initial width. 
Matrigel matrix (Basement Membrane Matrix, BD Biosciences, Italy) was kept at 4 °C for 3 
h, when 230 µL of Matrigel solution was added to each well of a 24-well plate. After gelling 
at 37°C for 30 min, gels were overlaid with 500 µL of medium containing 6 x 10
4
 HUVECs. 
The cells were incubated over Matrigel for 6 h to allow capillary tubes to form. Different 
concentrations of test compound were added in the cultures and incubated for different times, 
and the disappearance of existing vasculature was monitored and photographed (five fields for 
each well: the four quadrants and the center) at 10x magnification. Phase contrast images were 
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recorded using a digital camera and saved as TIFF files. Image analysis was carried out using 
ImageJ image analysis software, and the following dimensional parameters (percent area 
covered by HUVECs and total length of HUVECs network per field) and topological 
parameters (number of meshes and branching points per field) were estimated.
42
 Values were 
expressed as percent change from control cultures grown with complete medium. 
In vivo CAM assay in fertilized chicken eggs. Alginate pellets containing 0.1-1.0 pmol per 
pellet of TR-644 or CA4 were grafted on the CAM of fertilized chicken eggs at day 11. After 
72 h, new blood vessels converging toward the implant were counted at 5x magnification 
under a stereomicroscope. 
Antivascular activity in vivo. Six week old C57BL/6 mice (Charles River, Calco, Italy) were 
injected subcutaneously into the dorsolateral flank with 10
5
 BL6-B16 murine melanoma cells 
in 200 µL of PBS. When tumor volume reached 300 mm
3
, animals were treated 
intraperitoneally with 3g (30 mg/kg) dissolved in DMSO (50 µl). Twenty-four hours later, 
tumors were harvested, embedded in OCT-compound (Bio-Optica) and immediately frozen in 
liquid nitrogen for immunohistochemical analysis, as previously described.
43
 Excised tumors 
were cut with a cryostat into 4-5 μm sections. Immunohistochemistry was performed by 
staining samples with rat anti-mouse CD31 antibody (1:200; BD Biosciences) and 
biotinylated goat anti-rat secondary antibody (1:100; BD Biosciences). Quantification was 
performed by counting the number of CD31 positive vessels in 5 fields per section, using a 
40x objective. 
Antitumor activity in vivo. The in vivo cytotoxic activity of compound 3g was investigated 
using a syngeneic murine hepatocellular carcinoma cell line (BNL 1ME A.7R.1) in Balb/c 
mice.
40
 Male mice, 8 weeks old, were purchased from Harlan (S. Pietro al Natisone Udine, 
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Italy), and tumors were induced by a subcutaneous injection in their dorsal region of 10
7
 cells 
in 200 µL of sterile PBS. Animals were randomly divided into four groups, and, starting on 
the second day, the first group was daily dosed intraperitoneally with 7 µL/g of vehicle (0.9% 
NaCl containing 5% polyethylene glycol 400 and 0.5% Tween 80). Groups two and three 
were treated with compound 3g at the doses of 5 or 10 mg/kg body weight, respectively. The 
fourth group received the reference compound CA-4P at 5 mg/kg body weight. Both 
compound 3g and CA-4P were dissolved in vehicle. Tumor sizes were measured daily for 7 
days using a pair of calipers. Tumor volume (V) was calculated by the rotational ellipsoid 
formula: V = A x B
2
/2, where A is the longer diameter (axial) and B is the shorter diameter 
(rotational). All experimental procedures followed guidelines recommended by the 
Institutional Animal Care and Use Committee of Padova University. 
Statistical analysis. Unless indicated otherwise, results are presented as mean ± S.E.M. The 
differences between different treatments were analyzed using the two-sided Student’s t test. P 
values less than 0.05 were considered significant.  
Supporting information available. HPLC traces and HRMS spectrum of compounds 3g and 
3h. Molecular formula strings in csv format. This material is available free of charge via the 
Internet at http://pubs.acs.org. 
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Table 1. In vitro cell growth inhibitory effects of compounds 3a-l and CA-4 (1) 
 
 
Compd  
IC50 
a
 (nM) 
HeLa A549 HT-29 Jurkat RS 4;11 MCF-7 HL-60 
3a 260±50 5280±800 930±35 4100±200 430±97 7800±900 4400±200 
3b 1330±580 5470±700 1600±120 180±38 300±80 6600±310 2500±130 
3c >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 
3d >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 
3e 250±88 1570±430 240±60 210±20 39±9 7900±1300 470±30 
3f 1260±510 8900±1460 1400±540 2300±700 190±15 2900±400 3400±120 
3g 2±0.1 9±1.4 3±0.9 8±0.6 0.3±0.1 27±2 5±1 
3h 13±8 36±11 17±8 22±6 100±10 25±3 24±7 
3i 130±60 1270±400 290±30 30±5 1±0.1 520±40 320±17 
3j 270±80 1100±300 110±50 290±50 230±10 2100±90 590±50 
3k 2530±280 8900±1300 3200±210 3700±450 400±100 >10,000 4200±200 
3l 3280±370 7250±237 5300±290 9100±820 3000±400 >10,000 5500±540 
CA-4 4±1 180±30 3100±100 5±0.6 0.8±0.2 370±100 1±0.2 
a
IC50= compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the 
mean ± SE from the dose-response curves of at least three independent experiments. 
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Table 2. Cytotoxicity of 3c and 3f in human non-cancer cells 
 
a
 Compound concentration required to reduce cell growth by 50%. 
b
 PBL not stimulated with PHA. 
c
 PBL stimulated with PHA. 
Values are the mean ± SEM for three separate experiments. 
 
 
Cell line  
IC50 (µM)
 a
 
3g 3h 
PBLresting
b
 >10 >10 
PBLPHA
c
 >10 6.3±1.0 
HUVEC 0.75±0.4 0.22±0.1 
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Table 3. Inhibition of tubulin polymerization and colchicine binding by compounds 3e, 3g-j 
and CA-4 
 
Compound 
Tubulin assembly
a 
IC50±SD (M) 
Colchicine binding
b 
% inhibition±SD 
3e 7.5±0.5 n.d. 
3g 1.1±0.1 83±0.5 
3h 1.5±0.2 74±4.1 
3i 7.6±1.0 n.d. 
3j 6.4±0.9 n.d. 
CA-4 (1a) 1.1±0.1 99±0.1 
a
 Inhibition of tubulin polymerization. Tubulin was at 10 M. 
b
 Inhibition of [
3
H]colchicine binding. Tubulin, colchicine and tested compound were at 1, 5 and 5 M, 
respectively.  
n.d.: not determined 
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Figure Legends 
Figure 1. Proposed binding of 3g (represented in magenta) in the colchicine site of tubulin 
(PDB:3HKC). The co-crystallized ligand N-[2-[(4-Hydroxyphenyl)amino]-3-pyridinyl]-4-
methoxybenzenesulfonamide (ABT751) is represented in green.  
Figure 2. Percentage of cells in each phase of the cell cycle in Jurkat (Panel A) and HeLa 
(Panel B) cells treated with 3g or 3h at the indicated concentrations for 24 h. Cells were fixed 
and labeled with PI and analyzed by flow cytometry as described in the Experimental section. 
Panel C. Western blot analysis of some G2/M regulatory proteins after treatment with 3g or 
3h. HeLa cells were treated for 24 or 48 h with the indicated concentration of compound. The 
cells were harvested and lysed for the detection of cyclin B, p-cdc2
Y15
 and cdc25c expression. 
To confirm equal protein loading, each membrane was stripped and reprobed with anti--actin 
antibody. 
Figure 3. Flow cytometric analysis of apoptotic cells after treatment of HeLa cells with 3g or 
3h at the indicated concentrations after incubation for 24 (Panel A) or 48 h (Panel B). The 
cells were harvested and labeled with annexin-V-FITC and PI and analyzed by flow 
cytometry.  
Figure 4. A) Assessment of mitochondrial membrane potential (mt) after treatment of HeLa 
cells with compounds 3g or 3h. Cells were treated with the indicated concentration of 
compounds for 24 or 48 h and then stained with the fluorescent probe JC-1. Data are 
presented as mean ± S.E.M. of three independent experiments. B) Mitochondrial production 
of ROS in HeLa cells following treatment with compound 3g or compound 3h. After 24 or 48 
h incubations, cells were stained with H2-DCFDA and analyzed by flow cytometry. Data are 
presented as mean  S.E.M. of three independent experiments. 
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Figure 5. Western blot analysis of  H2AX, Bcl-2 Mcl-1, caspase-3, cleaved caspase-9 and 
PARP after treatment of HeLa cells with 3g or 3h at the indicated concentrations for the 
indicated times. To confirm equal protein loading, each membrane was stripped and reprobed 
with anti--actin antibody. 
Figure 6. Inhibition of mouse allograft growth in vivo by compound 3g. (A). Male mice were 
injected subcutaneously at their dorsal region with 10
7
 BNL 1MEA.7R.1 cells, a syngenic 
hepatocellular carcinoma cell line. Tumor-bearing mice were administered the vehicle, as 
control, or 3g at the doses of 5 mg/kg or 10 mg/kg or CA-4P (5 mg/kg) as reference 
compound. Injections were given intraperitoneally daily starting on day 1. The figure shows 
the average measured tumor volumes (A) and body weights of the mice (B) recorded at the 
beginning and at the end of the treatments. Data are presented as mean ± SEM of tumor 
volume and body weight at each time point for 5 animals per group. *p<0.01, vs. control.  
Figure 7. Compound 3g has antivascular activity in vitro. Panel A. Confluent HUVECs in a 
monolayer were wounded, and cells were treated with different concentrations of 3g and 
photographed at various times, 7x magnification; bar=100 µm. The dotted lines define the 
areas lacking cells. Panel B. The graph shows the quantitative effect of 3g. Migration was 
quantified by measuring the gap closure at the indicated times. Data are represented as mean ± 
S.E.M. of three independent experiments. *p<0.05, **p<0.01 vs control. Panel C. Inhibition 
of endothelial cell capillary-like tubule formation by 3g. Representative pictures (10x 
magnification; bar=100 µm) of preformed capillary-like tubules treated with increasing 
concentration of 3g for 1 h or 3 h. Panels D and E. Quantitative analysis of the effects of 3g 
on the dimensional and topological parameters of the preformed capillary-like tubule 
networks, after a 1 h (panel D) or a 3 h treatment (panel E). Data are represented as mean ± 
S.E.M. of three independent experiments. 
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Figure 8. In vivo effects of 3g on angiogenesis. A. The CAM assay. Alginate sponges 
embedded with FGF, a stimulator of blood vessel formation, in the presence of the indicated 
concentrations of 3g, were implanted on the top of the growing CAM on day 11 of 
development. On day 14, newly formed blood vessels converging toward the implants were 
counted microscopically. Data represent mean ±SEM of at least six eggs for each group. 
***p<0.001 vs control. B and C. Efficacy in vivo of 3g in a syngeneic mouse model. B. BL6-
B16 murine melanoma cells were injected in the right flank of C57BL/6 mice as described in 
the Experimental Section. Tumor tissues were embedded in OCT-compound and frozen for 
immunohistochemistry. CD31 immunohistochemistry and hematoxylin-eosin (HE) staining of 
tumor after i.p. treatment with 30 mg/kg of 3g (100x magnification). C. Quantitative analysis 
of tumor section stained with CD31 for blood vessel number. Data are represented as 
mean±SEM of five mice per group. *P < 0.05 versus control.  
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Chart 1. Chemical structures of CA-4 (1a), CA-4P (1b), 2-substituted-3-(3,4,5-
trimethoxybenzoyl)-6-methoxybenzo[b]furans 2, 2-alkoxycarbonyl-3-(3,4,5-
trimethoxyanilino)benzo[b]furan derivatives 3a-l. 
 
3a, R2=CH3, R4-7=H, 
3b, R5=C2H5, R4-7=H, 
3c, R2=CH3, R4=OCH3, R5-7=H
3d, R2=C2H5, R4=OCH3, R5-7=H
3e, R2=CH3, R5=OCH3, R4,6-7=H
3f, R2=C2H5, R5=OCH3, R4,6-7=H
3g, R2=CH3, R6=OCH3, R4-5,7=H
3h, R2=C2H5, R6=OCH3, R4-5,7=H
3i, R2=CH3, R7=OCH3, R4-6=H
3j, R2=C2H5, R7=OCH3, R4-6=H
3k, R2=CH3, R7=OC2H5, R4-6=H
3l, R2=C2H5, R7=OC2H5, R4-6=H
O
2
H3CO
R1=H, Br, CN, CO2CH3, alkyl,
alkylamine, aryl, heteroaryl
R2=H or OH
2a, R1=CO2CH3, R2=OH
O
O
O
R2
3a-l
NH
H3CO
H3CO OCH3
R4
R5
R6
R7
R
OCH3
H3CO
CH3O
H3CO
R=OH, Combretastatin A-4 (CA-4), 1a
R=OPO3Na2, CA-4P, 1b
1
H3CO
H3CO OCH3
O
R2
A
B
R1
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